HMGB1 and acute kidney injury: Furthermore, preclinical evidence supports the feasibility of HMGB1-targeted therapies in mitigating inflammation, oxidative stress, and cell death, offering hope for improved AKI management (Chen et al., 2011a; Lau et al., 2014; Zhao Z. et al., 2023).